Navigation Links
Igenica Appoints Thi-Sau Migone, Ph.D., as Chief Scientific Officer
Date:4/9/2013

BURLINGAME, Calif., April 9, 2013 /PRNewswire/ -- Igenica, Inc., an innovative biopharmaceutical company focused on the discovery and development of first-in-class antibody-based therapeutics for the treatment of cancer, today announced the appointment of Thi-Sau Migone , Ph.D., to the role of Chief Scientific Officer.

Dr. Migone brings wide-ranging experience in the discovery and development of novel therapeutic antibodies.  Dr. Migone joins Igenica from Human Genome Sciences, where she held a variety of executive positions and most recently served as Vice President of Research.  In that role, she led scientific programs ranging from early discovery through Biologics License Applications, including belimumab and raxibacumab, two antibody programs that reached regulatory approval under her scientific leadership.  Prior to Human Genome Sciences, Dr. Migone held research positions at DNAX Research Institute, the National Heart, Lung and Blood Institute and National Institute of Allergy and Infectious Diseases.  Dr. Migone received a doctoral degree in Biological Sciences from the University of Pavia, Italy.

"Dr. Migone has a track record of leading and advancing biotherapeutics programs from discovery to successful product approval," said Mary Haak-Frendscho , Ph.D., Chief Executive Officer of Igenica.  "She brings an exceptional skillset and talent to Igenica at a time of great promise for Igenica's platform and first-in-class antibody-based therapeutic programs."

"Igenica has developed an integrated suite of differentiated technologies and capabilities supporting the discovery of novel cancer targets, antibodies and antibody-drug conjugates.  The Company is building a pipeline of next-generation cancer therapeutics that have significant potential to improve outcomes for cancer patients," said Dr. Migone.  "I am delighted to have this opportunity to contribute to Igenica's success."

About Igenica, Inc.

Igenica, Inc. is a biopharmaceutical company pioneering breakthrough antibody-based cancer medicines. The company has integrated innovative technology platforms to address the major challenges to developing effective treatments for multiple oncology indications, with sTAg, a forward-looking proteomics approach to discovering novel tumor antigens, iTAb, a functional in vivo antibody screening approach, and next generation antibody-drug conjugate technology.  Igenica's technology platforms drive innovative drug discovery and promise to identify novel and more effective cancer therapeutics.

Igenica's Board of Directors includes David Goeddel , Ph.D., The Column Group; John Diekman , Ph.D., 5AM Ventures; Mark A. Goldsmith , M.D., Ph.D., Third Rock Ventures; Carl Gordon , Ph.D., CFA, Orbimed Advisors; Mary Haak-Frendscho , Ph.D., Igenica, Inc.; Robert Schreiber , Ph.D., Igenica Founder and Alumni Endowed Professor of Pathology and Immunology, Professor of Molecular Microbiology and Tumor Immunology Program Leader for the Siteman Comprehensive Cancer Center at Washington University School of Medicine.

Contact:
John K. Celebi , MBA
Chief Business Officer
Igenica, Inc.
(650) 231-4320


'/>"/>
SOURCE Igenica, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Igenica Closes $33 Million in Series C Funding
2. Igenica Appoints Mary Haak-Frendscho, Ph.D., as Chief Executive Officer
3. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
4. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
5. Nephros Appoints John C. Houghton as President and Chief Executive Officer
6. Elsevier Appoints New President of Elsevier CPM Resource Center
7. GenWay Biotech Appoints New Vice President of Custom/OEM
8. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
9. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
10. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
11. Hill-Rom Appoints Alton Shader President of Hill-Rom North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
(Date:9/28/2017)... -- Cohen Veterans Bioscience and Early Signal Foundation announce ... home sensors for real-time monitoring of patients with trauma-related ... organization focused on disruptive health solutions for rare disorders ... to record and integrate behavioral, cognitive, physiological and contextual ... ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology:
(Date:10/13/2017)... Las Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... of 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum ... CBD dose required and providing a CBD form that can be easily incorporated into ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
Breaking Medicine News(10 mins):